Massachusetts Financial Services Co. MA lowered its position in Silk Road Medical Inc (NASDAQ:SILK) by 0.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 275,619 shares of the company’s stock after selling 1,042 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Silk Road Medical were worth $8,966,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the stock. Bank of Montreal Can bought a new position in Silk Road Medical in the 2nd quarter worth $28,000. Elkfork Partners LLC bought a new position in Silk Road Medical in the 2nd quarter worth $30,000. Meadow Creek Investment Management LLC bought a new position in Silk Road Medical in the 2nd quarter worth $36,000. Steward Partners Investment Advisory LLC boosted its holdings in Silk Road Medical by 50.6% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,620 shares of the company’s stock worth $85,000 after buying an additional 880 shares during the period. Finally, Horan Securities Inc. bought a new position in Silk Road Medical in the 3rd quarter worth $33,000. 81.14% of the stock is owned by institutional investors.
In other Silk Road Medical news, CEO Erica J. Rogers sold 20,044 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $35.00, for a total transaction of $701,540.00. Following the completion of the transaction, the chief executive officer now owns 116,340 shares of the company’s stock, valued at approximately $4,071,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
SILK opened at $37.68 on Monday. The firm has a 50-day simple moving average of $33.22 and a two-hundred day simple moving average of $40.01. Silk Road Medical Inc has a 52 week low of $27.83 and a 52 week high of $51.50. The company has a debt-to-equity ratio of 0.58, a current ratio of 10.61 and a quick ratio of 13.38.
Silk Road Medical (NASDAQ:SILK) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The company had revenue of $17.00 million for the quarter, compared to the consensus estimate of $15.93 million. Silk Road Medical’s revenue was up 77.1% on a year-over-year basis. As a group, equities research analysts anticipate that Silk Road Medical Inc will post -7.82 EPS for the current fiscal year.
Silk Road Medical Company Profile
Silk Road Medical, Inc operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
Featured Article: How liquidity affects the bid-ask spread
Want to see what other hedge funds are holding SILK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silk Road Medical Inc (NASDAQ:SILK).
Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.